These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 19702237)
21. Licensing veterinary biologics in the United States. Espeseth DA Dev Biol Stand; 1992; 79():17-25. PubMed ID: 1286752 [TBL] [Abstract][Full Text] [Related]
22. Legal developments relevant to FDA authority. Meron D Food Drug Law J; 2007; 62(2):441-4. PubMed ID: 17632974 [No Abstract] [Full Text] [Related]
23. The regulation of medicinal products derived from human blood or plasma in the European Community. Brunko P Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813 [No Abstract] [Full Text] [Related]
24. The EEC and the regulation of blood derivatives. Horaud F Dev Biol Stand; 1993; 81():273-6. PubMed ID: 8174814 [No Abstract] [Full Text] [Related]
25. Scientific and regulatory considerations on the immunogenicity of biologics. Shankar G; Shores E; Wagner C; Mire-Sluis A Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266 [TBL] [Abstract][Full Text] [Related]
27. Laboratory control of biological products in Latin America. Greenberg L Bull Pan Am Health Organ; 1975; 9(1):27-31. PubMed ID: 1148451 [TBL] [Abstract][Full Text] [Related]
28. A national drug agency. West R; Borden EK; Collet JP; Rawson NS; Tonks RS CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372 [No Abstract] [Full Text] [Related]
29. Application of good manufacturing practice regulations to investigational biologic products. Goebel PW J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865 [No Abstract] [Full Text] [Related]
30. We need Romanow's National Drug Agency. CMAJ; 2003 Feb; 168(3):249, 251. PubMed ID: 12566321 [No Abstract] [Full Text] [Related]
31. Revisioning the oversight of research involving humans in Canada. Downie J; McDonald F Health Law J; 2004; 12():159-81. PubMed ID: 16539080 [No Abstract] [Full Text] [Related]
32. In vitro fertilization: mandatory IVF coverage in health insurance. Kerr L Fed Insur Corp Couns Q; 1993; 43():329-51. PubMed ID: 11652706 [No Abstract] [Full Text] [Related]
33. "New approach" as Health Canada seeks conditional licences for drugs, new pediatric office. Eggertson L CMAJ; 2005 Mar; 172(7):864. PubMed ID: 15743911 [No Abstract] [Full Text] [Related]
34. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Rauws AG; Groen K Chirality; 1994; 6(2):72-5. PubMed ID: 8204416 [TBL] [Abstract][Full Text] [Related]
35. The economics of health in a post-industrial society. Fuchs VR Public Interest; 1979; (56):3-20. PubMed ID: 10308941 [No Abstract] [Full Text] [Related]
36. Regulatory framework of immunologicals in the European Union. Sauer F Biologicals; 1994 Dec; 22(4):307-11. PubMed ID: 7779353 [No Abstract] [Full Text] [Related]
38. The application of the Canadian Charter of Rights and Freedoms to the regulation of health professionals: anaemic rights and prescriptions for change. Rees OM; Gonsalves A Health Law Can; 2010 Jun; 30(4):203-18. PubMed ID: 20738080 [No Abstract] [Full Text] [Related]